Adamis Pharma: Climbs on FDA acceptance to review opioid overdose treatment

DMK Pharmaceuticals

09/06/2021 14:22

** Shares of drug developer  ADMP.O  climb ~13% to $1.14
premarket, among the most heavily traded stocks across U.S.
exchanges
    ** Co says U.S. FDA has accepted for review ADMP's marketing
application for ZIMHI - its naloxone injection product candidate
to treat opioid overdose  urn:newsml:reuters.com:*:nGNX7wzLYX
    ** FDA has determined that the application was sufficiently
complete to permit a substantive review - co
    ** The agency has set a target date of Nov. 12, 2021
    ** Naloxone blocks or reverses effects of the opioid,
including extreme drowsiness, slowed breathing and loss of
consciousness
    ** Stock up 108.2% since Dec. 31, 2020

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))